Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

FAMS aanpassen om CGM-gebruik te optimaliseren bij opkomende volwassenen met diabetes type 1

30 oktober 2026 bijgewerkt door: Lindsay Mayberry, Vanderbilt University Medical Center

The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Gedetailleerde beschrijving

FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication).

Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.

Studietype

Ingrijpend

Inschrijving (Geschat)

140

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • California
      • Los Angeles, California, Verenigde Staten, 90027
        • Children's Hospital of Los Angeles
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84112
        • University of Utah

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 24 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

PERSONS WITH DIABETES

  • Ages 18-24
  • Have a diagnosis of T1D and has been taking insulin for at least one year
  • Comfortable sending and receiving texts
  • Can speak, read, and write in English
  • Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2)
  • Using a continuous glucose monitor (CGM)

SUPPORT PERSONS

  • Age 18 or older
  • Can speak, read, and write in English or Spanish
  • Comfortable sending and receiving texts

Exclusion Criteria:

PERSONS WITH DIABETES

  • Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness)
  • Plans to live outside the country during the study period

SUPPORT PERSONS

  • Shares a phone with the person with diabetes
  • Plans to live outside of the country during the study period

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: FAMS-T1D

Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes.

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled.

Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.

Andere namen:
  • Activering van familie/vrienden om zelfzorg te motiveren voor mensen met diabetes type 1

Quality digital resources about diabetes management provided upon enrollment and during the study.

Placebo-vergelijker: Digital resources for diabetes

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Quality digital resources about diabetes management provided upon enrollment and during the study.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
CGM frequency of use during the intervention period
Tijdsspanne: Baseline and 6 months post-baseline

Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better

Baseline and 6 months post-baseline
CGM frequency of use during the intervention period
Tijdsspanne: Baseline and 6 months post-baseline

Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)

Baseline and 6 months post-baseline
Gaps in CGM use
Tijdsspanne: 6 months post-baseline

Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

6 months post-baseline

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
CGM behavioral responses during the intervention period
Tijdsspanne: Baseline and 6 months post-baseline

Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)

Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
Tijdsspanne: Baseline and 6 months post-baseline

Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

Baseline and 6 months post-baseline
Barriers to CGM use during the intervention period
Tijdsspanne: Baseline and 6 months post-baseline

Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)

Baseline and 6 months post-baseline
CGM satisfaction during the intervention period
Tijdsspanne: Baseline and 6 months post-baseline

Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)

Baseline and 6 months post-baseline

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Data sharing during the intervention period
Tijdsspanne: 6 months post-baseline

Number of data sharing relationships, between groups; more is better

6 months post-baseline
Satisfaction with data-sharing relationships
Tijdsspanne: 6 months post-baseline

Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better

6 months post-baseline

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

30 april 2023

Primaire voltooiing (Geschat)

31 januari 2027

Studie voltooiing (Geschat)

30 april 2027

Studieregistratiedata

Eerst ingediend

24 april 2023

Eerst ingediend dat voldeed aan de QC-criteria

9 mei 2023

Eerst geplaatst (Werkelijk)

11 mei 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

30 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.

IPD-tijdsbestek voor delen

After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.

IPD-toegangscriteria voor delen

Contact the principal investigator

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren